Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their upcoming webinar, “De-risking Bispecifics Early-on: How tight is too tight? How weak is too weak?” will occur on Wednesday, April 6, 2022 at 2p.m. ET/ 11A.M. PT.
| CONCORD, Mass., March 31, 2022 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their upcoming webinar, “De-risking Bispecifics Early-on: How tight is too tight? How weak is too weak?” will occur on Wednesday, April 6, 2022 at 2p.m. ET/ 11A.M. PT.
In this webinar, Dr. John Burke, Co-founder, President and CEO of Applied BioMath will present two bispecific antibody case studies, which includes an antibody-ligand fusion and a T-Cell engager, where Applied BioMath Assess™, a web enabled MID3 analysis, helped to rapidly generate actionable hypotheses early in a project to impact critical thinking and portfolio decisions. “Bispecific antibody properties that are optimal or project killing are difficult to predict a priori to or early-on in a project but are essential to enabling hypothesis generation, informing critical thinking, and informing go/no-go decisions,” said Dr. John Burke. “With Applied BioMath Assess™, project teams are able to quickly explore many more “what if” questions than would be possible without computational tools due to complexity of the therapeutic and biology as well as the combinatorial experimental complexities. The use of cloud computing, high-performance computing, interactive plots, and pre-built pharmacology models enable users to quickly gain a quantitative understanding of the risks and advantages in developing exciting new medicines.” Applied BioMath’s solutions, which focus on quantitatively integrating knowledge about therapeutics with an understanding of its mechanism of action in the context of human disease mechanisms, are leveraged across the entire R&D spectrum from early research through all phases of clinical trials. Their approach involves working with clients to develop the appropriate mathematical strategy for each unique project, with common biosimulation software and services strategies including systems pharmacology, mechanistic modeling, PK/PD, bioinformatics and machine learning, clinical pharmacology, clinical PK/PD, and pharmacometrics. To learn more or register for the webinar, please visit https://www.appliedbiomath.com/news-resources/events. About Applied BioMath Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC. Contact:
SOURCE Applied BioMath, LLC |
View original content to download multimedia:
